Tiomolibdate Choline

Summary

Tiomolibdate Choline (CHEMBL4594259) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including wilson disease and melanoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 17

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594259
Name	Tiomolibdate Choline
Type	Small molecule
Max phase	3

Also known as: ALXN-1840, Alxn1840, ALXN1840, Atn-224, ATN-224, Bis(choline) tetrathiomolybdate, Bis(choline)tetrathiomolybdate, Bis-choline tetrathiomolybdate, Choline tetrathiomolybdate, Tiomolibdate choline, WTX-101, Wtx101

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Wilson disease	3	MONDO:0010200	MONDO:0010200
melanoma	2	MONDO:0005105	EFO:0000756
breast neoplasm	2	MONDO:0021100	MONDO:0007254

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 17.

Phase distribution

Phase	Trials
PHASE1	8
PHASE2	5
PHASE3	2
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03403205	PHASE3	TERMINATED	Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
NCT05047523	PHASE3	TERMINATED	Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
NCT00352742	PHASE1/PHASE2	TERMINATED	A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma
NCT00383851	PHASE2	UNKNOWN	Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma
NCT00405574	PHASE2	UNKNOWN	Study of ATN-224 in Patients With Prostate Cancer
NCT02273596	PHASE2	COMPLETED	Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients
NCT04422431	PHASE2	COMPLETED	Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840
NCT04573309	PHASE2	COMPLETED	Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
NCT04526197	PHASE1	COMPLETED	Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.
NCT04526210	PHASE1	COMPLETED	Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
NCT04560816	PHASE1	COMPLETED	A Study of the Cardiac Effects of ALXN1840 in Healthy Adults
NCT04594252	PHASE1	COMPLETED	Copper Balance in Healthy Participants Administered ALXN1840
NCT04610580	PHASE1	COMPLETED	Bioavailability Study of 2 Oral Formulations of ALXN1840
NCT05303324	PHASE1	COMPLETED	Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults
NCT05319899	PHASE1	COMPLETED	A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults
NCT05641311	PHASE1	COMPLETED	Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants
NCT05686564	Not specified	NO_LONGER_AVAILABLE	Early Access Program for ALXN1840 in Patients With Wilson Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).